RetaSlim 30mg
RetaSlim 30mg
Couldn't load pickup availability
RetaSlim is an innovative triple agonist of the GLP-1, GIP, and glucagon receptors (GCGR), designed to effectively promote weight loss, manage blood sugar, and improve metabolic health.
Purity: 99.4%
Amino acid sequence: H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Molecular formula: C221H342N46O68
Molecular weight: 4731.33±1 Da
| Effect | Description |
| Significant weight loss | Activation of GLP-1, GIP and GCGR enhances weight loss by up to 29% of baseline by suppressing appetite and increasing energy expenditure. |
| Blood sugar control | Stimulation of insulin secretion and suppression of glucagon improves glycemic control and reduces the risk of type 2 diabetes. |
| Acceleration of fat metabolism | Activation of glucagon receptors accelerates lipolysis and the conversion of adipose tissue into energy. |
| Cardiovascular support | Lowering cholesterol, triglycerides and improving blood pressure. |
| Anti-inflammatory and neuroprotective action | Reduction of inflammatory markers and potential slowing of cognitive decline. |
What aspects of health can it support?
- Weight loss in obesity
- Glucose and insulin resistance control
- Metabolic health support and prevention of metabolic syndrome
- Improvement of lipid profile and blood pressure
- Potential neuroprotection and anti-inflammatory effects
Comparison with similar peptides and telomerase activators
Unlike other GLP-1 agonists, RetaSlim combines the action of three receptors (GLP-1, GIP, GCGR), providing greater effectiveness in weight loss, blood sugar control, and metabolic improvement. The drug maintains stable results even after 68 weeks, without the sharp plateaus often observed with similar products.
Side Effects and Important Warnings
- Nausea, vomiting, or diarrhea may occur during initial use.
- RetaSlim is intended for investigation and research use only.
Legal and Ethical Warning
RetaSlim should be used strictly as research use.
List of scientific literature and sources
Phase 2 clinical trial of the triple agonist retatrutide in obesity (NEJM)
Phase 2 study of retatrutide in patients with type 2 diabetes (The Lancet)